A Middle-Aged Beckman Experiences Growing Pains
In the early 1990s, Beckman was hit by adverse market conditions in its two major businesses, life sciences and clinical diagnostics. A strategic restructuring in the past two years has left it in strong financial shape and focused it on new areas of growth.
You may also be interested in...
With the Coulter integration successful, Beckman Coulter looks for high-growth opportunities outside of its traditional businesses. Beckman, through internal efforts in its life sciences business and a series of small alliances, is making a play in genomics and proteomics. In addition to building up near-term revenues, the aim is to find new "content" in the form of assays for its clinical business.
CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.
Despite Mark’s relatively upbeat attitude, FDA experts warn that even absent a government shutdowns or minimally impactful ones, the current cycle of continuing resolutions and the lingering threat of budget sequestration is harmful to the agency’s operation.